pharmaphorum January 13, 2022
EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis.
Only a regulatory framework that “embraces a culture of excellence and innovation” will make Europe a world leader in life sciences and ensure people can reap the benefits of life-changing new treatments.
That’s according to the EFPIA’s analysis of the region’s regulatory framework, which compares the timelines of national regulatory agencies, and suggests key areas for change as the European Commission (EC) prepares to review pharmaceutical legislation.
Innovation and unmet need
The EC’s upcoming review of pharmaceutical regulation, part of the EU Pharmaceuticals Strategy, comes as the region faces substantial unmet need in disease areas from cancers to Alzheimer’s, liver disease to CNS disorders.
The...
Today's Sponsors
Today's Sponsor